{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T10:50:07Z","timestamp":1792839007700,"version":"4.5.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2130,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,11]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>\n                      Exclusive monotherapy with zinc in symptomatic Wilson disease is controversial. Seventeen symptomatic patients with Wilson disease were treated with zinc only. The mean age at diagnosis and start of treatment was 18 years (range 13\u201326) with approximately half presenting as adolescents. Presentation was exclusively hepatic, exclusively neurologic, and combined in seven, five, and five patients, respectively. The median follow-up was 14 years (range 2\u201330). At baseline, two of the 12 patients with hepatic disease exhibited decompensated cirrhosis, five exhibited compensated cirrhosis, and five had less severe disease. Both patients with decompensated cirrhosis improved to a compensated state after initiation of therapy. Two of the five patients with initial compensated cirrhosis progressed to decompensated state, and three remain stable. Three of the five patients with moderate or mild liver disease remain stable and two improved. Apart from decreasing bilirubin levels, no significant changes occurred in the liver biochemistry or function during long-term follow-up. Nine of 10 neurologic patients improved markedly and one deteriorated. Two patients with exclusively neurologic presentation developed liver disease during zinc treatment. Two patients with exclusively hepatic presentation developed mild neurologic symptoms. According to 24-hour urinary copper excretions (213 \u00b1 38 versus 91 \u00b1 23 \u03bcg:\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.01) and serum non\u2013ceruloplasmin-bound copper concentrations (11 \u00b1 2 versus 7 \u00b1 1 \u03bcg\/dL:\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.1) at the end of follow-up, the efficacy of decoppering was less in the exclusively hepatic than in the neurologic group. The prescribed zinc dose and 24-hour urinary zinc excretions tended to be less in the exclusively hepatic group.\n                      <jats:italic toggle=\"yes\">Conclusion:<\/jats:italic>\n                      The outcome of exclusive zinc therapy is generally good in cases of neurologic disease. A less satisfactory outcome in hepatic disease may relate to less efficient decoppering. (Hepatology 2009.)\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hep.23182","type":"journal-article","created":{"date-parts":[[2009,7,20]],"date-time":"2009-07-20T09:54:56Z","timestamp":1248083696000},"page":"1442-1452","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":90,"title":["Long-term exclusive zinc monotherapy in symptomatic Wilson disease: Experience in 17 patients #"],"prefix":"10.1097","volume":"50","author":[{"given":"Francisca H. H.","family":"Linn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick H. J.","family":"Houwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"van Hattum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"van der Kleij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel J.","family":"van Erpecum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-16-20241201","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1053\/jhep.2003.50252","article-title":"A practice guideline on Wilson disease.","volume":"37","author":"Roberts","year":"2003","journal-title":"HEPATOLOGY"},{"key":"R2-16-20241201","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1002\/hep.22261","article-title":"Diagnosis and treatment of Wilson disease: an update.","volume":"47","author":"Roberts","year":"2008","journal-title":"HEPATOLOGY"},{"key":"R3-16-20241201","first-page":"197","article-title":"Chelation treatment of neurological Wilsons disease.","volume":"86","author":"Walshe","year":"1993","journal-title":"Q J Med"},{"key":"R4-16-20241201","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/archneur.1987.00520170020016","article-title":"Worsening of neurologic syndrome in patients with Wilsons disease with initial penicillamine therapy.","volume":"44","author":"Brewer","year":"1987","journal-title":"Arch Neurol"},{"key":"R5-16-20241201","doi-asserted-by":"crossref","first-page":"314","DOI":"10.7326\/0003-4819-99-3-314","article-title":"Oral zinc therapy for Wilsons disease.","volume":"99","author":"Brewer","year":"1983","journal-title":"Ann Intern Med"},{"key":"R6-16-20241201","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S0022-2143(98)90039-7","article-title":"Treatment of Wilsons disease with zinc: XV longterm followup studies.","volume":"132","author":"Brewer","year":"1998","journal-title":"J Lab Clin Med"},{"key":"R7-16-20241201","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/BF00868525","article-title":"Effects of longterm treatment in Wilsons disease with Dpenicillamine and zinc sulphate.","volume":"243","author":"Czlonkowska","year":"1996","journal-title":"J Neurol"},{"key":"R8-16-20241201","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0022-510X(87)90116-X","article-title":"Management of Wilsons disease with zinc sulphate. Experience in a series of 27 patients.","volume":"77","author":"Hoogenraad","year":"1987","journal-title":"J Neurol Sci"},{"key":"R9-16-20241201","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000115077","article-title":"Oral zinc sulphate as longterm treatment in Wilsons disease (hepatolenticular degeneration).","volume":"18","author":"Hoogenraad","year":"1979","journal-title":"Eur Neurol"},{"key":"R10-16-20241201","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.braindev.2005.08.008","article-title":"Paradigm shift in treatment of Wilsons disease: zinc therapy now treatment of choice.","volume":"28","author":"Hoogenraad","year":"2006","journal-title":"Brain Dev"},{"key":"R11-16-20241201","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/archneur.60.5.737","article-title":"Molecular diagnosis and prophylactic therapy for presymptomatic Chinese patients with Wilson disease.","volume":"60","author":"Wu","year":"2003","journal-title":"Arch Neurol"},{"key":"R12-16-20241201","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.lab.2005.01.007","article-title":"Treatment of Wilsons disease with zinc from the time of diagnosis in pediatric patients: a singlehospital, 10year followup study.","volume":"145","author":"Marcellini","year":"2005","journal-title":"J Lab Clin Med"},{"key":"R13-16-20241201","first-page":"447","article-title":"Maintenance treatment of Wilsons disease with oral zinc. Apropos of a child treated for 4 years.","volume":"42","author":"Alexiou","year":"1985","journal-title":"in French Arch Fr Pediatr"},{"key":"R14-16-20241201","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/003693305700200504","article-title":"Cerebral vascular accidents in patients over the age of 60. II. Prognosis.","volume":"2","author":"Rankin","year":"1957","journal-title":"Scott Med J"},{"key":"R15-16-20241201","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1148\/radiology.198.2.8596862","article-title":"Wilson disease: findings at MR imaging and CT of the brain with clinical correlation.","volume":"198","author":"van Wassenaervan Hall","year":"1996","journal-title":"Radiology"},{"key":"R16-16-20241201","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/01.mcg.0000225670.91722.59","article-title":"Diagnosis and management of Wilsons disease: results of a single center experience.","volume":"40","author":"Medici","year":"2006","journal-title":"J Clin Gastroenterol"},{"key":"R17-16-20241201","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/j.1365-2036.2009.03959.x","article-title":"Systematic review: clinical efficacy of chelator agents and zinc in the initial treatment of Wilson disease.","volume":"29","author":"Wiggelinkhuizen","year":"2009","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.23182","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200911000-00016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T08:21:19Z","timestamp":1733041279000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200911000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.23182","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1383980.856082","asserted-by":"object"}]},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}